Get the latest news, insights, and market updates on MESO (Mesoblast Limited). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
ASX Growth Stocks With High Insider Ownership
The Australian market has recently experienced a mixed performance, with materials dragging down the indices while energy stocks showed resilience amid shifting global economic sentiments. In this context, growth companies with high insider ownership can be particularly appealing as they often indicate strong internal confidence and alignment of interests, making them worth considering in today's fluctuating market environment. Oct 22, 2025 - $MESO
Is Now the Right Moment for Mesoblast After a 82% 12-Month Surge?
If you’ve been eyeing Mesoblast’s chart lately, you’re not alone. The stock has been a talking point for anyone interested in biotech’s dramatic swings, and with good reason. Over just the past 12 months, Mesoblast shares have soared 82.2%, catching the attention of both growth seekers and value hunters. While the last week saw a pullback of 5.7%, and the stock is still down 20.6% year-to-date, those longer-term gains—almost tripling over three years—are tough to ignore. These wild moves are... Oct 21, 2025 - $MESO
Mesoblast (ASX:MSB) SecurES Permanent J-Code for Ryoncil—What Does This Mean for Broader Adoption?
Earlier this month, Mesoblast announced that its therapy Ryoncil received a permanent Healthcare Common Procedure Coding System (HCPCS) J-Code from the US Centers for Medicare and Medicaid Services, effective October 1, enabling standardized reimbursement for hospitals and clinics. This formal recognition by CMS is a key step in facilitating broader access for patients and simplifying reimbursement processes for providers, supporting increased adoption of the therapy. We’ll explore how the... Oct 20, 2025 - $MESO
Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch
Activity Report for Quarter Ended September 30, 2025 (Appendix 4C)NEW YORK, Oct. 19, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the first quarter ended September 30, 2025. Mesoblast Chief Executive Dr. Silviu Itescu said, “Revenues from sales of Ryoncil® continue to increase, driven by greater physician adoption with reimbursement from both comm Oct 19, 2025 - $MESO
Mesoblast’s Ryoncil Gains Permanent CMS J-Code for Billing and Reimbursement
Mesoblast Limited (NASDAQ:MESO) is one of the best hot stocks to invest in. On October 3, Mesoblast Limited announced that its product Ryoncil (remestemcel-L-rknd) was assigned a specific Healthcare Common Procedure Coding System/HCPCS J-Code by the US Medicare & Medicaid Services/CMS. The new permanent J-Code, J3402, became active for billing and reimbursement on October 1. […] Oct 16, 2025 - $MESO
Ryoncil® Revenues Increase 66% in Second Quarter Post Launch
NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue of US$21.9 million on Ryoncil® (remestemcel-L-rknd) sales for the quarter ended September 30, 2025. This represents a 66% increase on the prior quarter ended June 30, 2025, with similar gross to net adjustment. Ryoncil® is the first mesenchymal stromal cell (MSC) product approved by the U.S. Food and Drug Adm Oct 6, 2025 - $MESO
Mesoblast (ASX:MSB): Assessing Valuation Following Recent Share Price Surge
Mesoblast (ASX:MSB) shares have delivered standout gains lately, with the stock up 42% over the past month and nearly 70% higher over the past 3 months. Investors seem to be re-evaluating the outlook. See our latest analysis for Mesoblast. Mesoblast’s recent share price surge is part of an encouraging turnaround, reflecting shifting sentiment after a rocky period earlier in the year. While momentum has clearly been building in the last few months, the 1-year total shareholder return of 85%... Oct 4, 2025 - $MESO
Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access
NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that a specific Healthcare Common Procedure Coding System (HCPCS) J-Code assigned to Ryoncil® (remestemcel-L-rknd) by United States Medicare & Medicaid Services (CMS) became active for billing and reimbursement on October 1, 2025.1 Formal recognition by CMS is a significant milestone for Ryoncil® as the product becomes eas Oct 3, 2025 - $MESO
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple